AbbVie, emraclidine and schizophrenia

AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. | The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie about $3.
AbbVie sees $3.5B impairment charge related to emraclidine
In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the
Abbvie to record $3.5 bln charge related to schizophrenia drug
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.
AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel Drug
AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug
Key Takeaways AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics.The biotech company reported in November that the schizophrenia drug,
AbbVie to record $3.5B impairment charge for Cerevel drug
AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, which it acquired through its acquisition of Cerevel Therapeutics last year. The drugmaker disclosed in November that two Phase 2 studies of the drug failed to meet their primary endpoint.
Abbvie to record $3.5 billion charge related to schizophrenia drug
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
pharmaphorum2d
Advantage BMS as AbbVie drug fails schizophrenia trials
Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.
Nasdaq1mon
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company lost 12.6% on Monday in response to the disappointing news.
Business Insider2mon
AbbVie ‘pain’ is Bristol Myers ‘gain’ after emraclidine fails, says Truist
Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia trials, which the firm sees as a negative for AbbVie and ...
pharmaphorum6d
Neurocrine slides as schizophrenia data disappoints
Neurocrine's drug acts as a muscarinic M4 selective agonist, while KarXT targets M1 and M4 receptors and emraclidine is described as a muscarinic M4 receptor-positive allosteric modulator (PAM).
Mena FN2mon
Abbvie Provides Update On Phase 2 Results For Emraclidine In Schizophrenia
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO ...
Nasdaq1mon
AbbVie price target lowered to $215 from $226 at Citi
The firm says the pivotal Phase 2 data for AbbVie’s emraclidine “surprisingly failed” to demonstrate a statistically significant change from baseline in the Positive and Negative Symptom ...
Yahoo Finance2mon
Why AbbVie Stock Was Getting Mashed on Monday
Schizophrenia drug didn't do well in the lab Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary endpoint in a phase 2 trial.